Entry Detail



General Information

Database ID:exR0353924
RNA Name:hsa-let-7b-5p
RNA Type:miRNA
Chromosome:chr22
Starnd:+
Coordinate:
Start Site(bp):46113691End Site(bp):46113712
External Links:hsa-let-7b-5p



Disease Information

Disease Name:Glioblastoma Multiforme
Disease Category:Cancers
MeSH ID:D005909
Type:Neoplasms/Neoplasms, Glandular and Epithelial
Alias:Glioblastoma//Glioblastomas//Astrocytoma, Grade IV//Astrocytomas, Grade IV//Grade IV Astrocytoma//Grade IV Astrocytomas//Glioblastoma Multiforme//Giant Cell Glioblastoma//Giant Cell Glioblastomas//Glioblastoma, Giant Cell//Glioblastomas, Giant Cell



Expression Detail

GEO ID:GSE93850
Description:Serum miRNAs in Patients with Glioblastoma Multiforme
Experimental Design:Cancer vs Control
Case Disease Type:Glioblastoma Multiforme
Case Disease SubType:NA
Case Sample:Glioblastoma Multiforme
Control Sample:Healthy
Number of Case:22
Number of Control:8
Number of Samples:30





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
TRIM65
chr17
75880335
75896951
-
C19orf53
chr19
13774456
13778773
+
C16orf58
chr16
31489471
31509309
-
TPP1
chr11
6612768
6619448
-
TBC1D13
chr9
128787253
128810430
+
MARCKSL1
chr1
32333839
32336233
-
TECPR2
chr14
102362941
102502477
+
TNRC6B
chr22
40044817
40335808
+
LRIG3
chr12
58872149
58920522
-
ARHGAP28
chr18
6729718
6915716
+
BACH1
chr21
29194071
29630751
+
LIMD1
chr3
45555394
45686341
+
BLOC1S6
chr15
45587214
45615945
+
PPARA
chr22
46150521
46243756
+
RTKN
chr2
74425835
74442422
-
HMGA2
chr12
65824131
65966295
+
YOD1
chr1
207043849
207052980
-
GOLGA4
chr3
37243177
37366751
+
ZNF652
chr17
49289206
49362473
-
MIER3
chr5
56919602
56971675
-
AP1S1
chr7
101154456
101161596
+
RANBP2
chr2
108719482
108785809
+
RAB40C
chr16
589357
629272
+
PDPR
chr16
70113626
70162537
+
TRAPPC10
chr21
44012309
44106552
+
COIL
chr17
56938199
56961050
-
BCAM
chr19
44809071
44821421
+
PHC3
chr3
170086732
170181749
-
CREM
chr10
35126791
35212958
+
ACP1
chr2
264140
278283
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000247
chr10
74474868
74475660
+
hsa_circ_0000987
chr2
30748452
30756180
+
hsa_circ_0000246
chr10
74468040
74475660
+
hsa_circ_0000018
chr1
15860731
15863309
+
hsa_circ_0000038
chr1
28800065
28802803
+
hsa_circ_0000799
chr17
65941524
65972074
+
hsa_circ_0001164
chr20
45891031
45923523
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC006064.5
chr12
6510275
6510522
+
AC074117.1
chr2
27356246
27367622
+
AC109460.3
chr16
28974804
28990775
+
AC124045.1
chr3
44667412
44669364
+
AP000766.1
chr11
107312132
107316271
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
KCNQ1OT1
chr11
2608328
2699994
-
LINC00265
chr7
39733430
39793092
+
LINC02381
chr12
54126082
54147485
+
MIRLET7BHG
chr22
46053869
46113928
+
NEAT1
chr11
65422774
65445540
+
NUTM2A-AS1
chr10
87201647
87342612
-
SNHG16
chr17
76557764
76565348
+
SNHG4
chr5
139274102
139284899
+
TMPO-AS1
chr12
98512973
98516422
-
XIST
chrX
73820649
73852723
-
ZNF436-AS1
chr1
23368997
23371839
+
Display:



Experiment Detail

GEO ID:GSE93850
Sample Source:Blood
Source Fraction:Serum
Platform:GPL22948
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1032
Sample treatment protocol:NA
RNA Extract protocol:Serum total RNA was isolated from serum samples using the Plasma/Serum Circulating and Exosomal RNA Purification Mini Kit (Slurry Format) (Norgen Biotek Corporation, Thorold, Ontario, Canada)
RNA library preparation protocol:0.3ug of total RNA of intrahepatic cholangiocarcinoma/normal intrahepatic bile duct tissue was employed with 100 nmol/L of pCp-DY547 (Dharmacon, Lafayette, CO, USA) and 15 Units of T4 RNA ligase (USB, Cleveland, Oh, USA) in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:28931080
Title:Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma
Author:Wang ZQ, Zhang MY, Deng ML, Weng NQ, Wang HY,Wu SX
Journal:PLoS One. 2017 Sep 20;12(9):e0184969.
Description:we investigated whether 3 of the 19 miRNAs in serum could be used as prognostic biomarkers for patients with GBM.